Biogen’s Biosimilars Sales Rise, But Future Still Unknown
As Off-Patent Competition Made A Dent In Firm’s Branded MS Portfolio
Biogen has yet again hinted about “strategic alternatives” for its biosimilars business albeit with no clear future plans, while its branded multiple sclerosis portfolio fights off generic and biosimilar competitors.
